Eupraxia Pharmaceuticals' EP-104GI Seen Offering Distinct Approach to Eosinophilic Esophagitis, RBC Says

MT Newswires Live11-10

Eupraxia Pharmaceuticals' (EPRX) once-yearly EP-104GI injection could serve a distinct group of patients with eosinophilic esophagitis, RBC Capital Markets said in a Monday note.

The investigational treatment combines a US Food and Drug Administration approved corticosteroid with the company's DiffuSphere delivery platform designed to maintain drug levels in the esophagus for nine to 12 months following a single endoscopic administration, according to the note.

Early-stage phase 1b and 2a data showed about 80% symptomatic remission and a clean safety profile, RBC said. A phase 2b interim data readout is expected in the first two weeks of December, the firm said.

RBC initiated coverage of Eupraxia Pharmaceuticals with an outperform, speculative risk rating and $14 price target.

Eupraxia Pharmaceuticals shares were 8.7% higher in Monday trading.

Price: 7.49, Change: +0.60, Percent Change: +8.71

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment